Retour à la liste des essais cliniquesSarcomas

ADCT-601-102

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

Ouvert à Paris depuis le : 19/07/2024
Public cible : Adult
Phase : Phase I

Description de l'essai

Identify recommended phase 2 dose (RP2D) and/or maximum;tolerated dose (MTD), and characterize the safety and tolerability;of ADCT-601 monotherapy and in combination with gemcitabine.

Url of the trial